Filing Flows › Neuroone Medical Technologies (NMTC) › Q2 FY26
Neuroone Medical Technologies (NMTC) Q2 FY26 earnings results (second quarter fiscal 2026)
10-Q filed May 12, 2026
Neuroone Medical Technologies (NMTC) reported revenue of $1.9M for the second quarter fiscal 2026 (Q2 FY26), +34% from a year earlier and -36% from the quarter before. Operating margin was -128.7%, net loss $2.4M (127.9% of revenue).
Neuroone Medical Technologies, Q2 FY26: revenue $1.9M (+34% year over year), operating margin -128.7%, net loss $2.4M, operating cash flow −$1.3M. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.9M | -36% | +34% |
| Operating profit | −$2.4M | — | — |
| Net earnings | −$2.4M | — | — |
| Operating cash flow | −$1.3M | — | — |
What changed
Revenue was $1.9M in Q2 FY26, up 34% year over year and down 36% from the previous quarter.
Gross margin was 53.2%, down 2.4 points from Q2 FY25. Operating costs exceeded revenue by $2.4M, an operating margin of -128.7%. Operating expenses fell 2% while revenue rose 34%. The quarter ended with a net loss of $2.4M, wider than the previous quarter's $1.4M loss.
Operating cash flow was −$1.3M. Non-cash charges added back $60K of depreciation and amortization and $342K of share-based compensation. Working capital and other items added $651K. Capital expenditures of $39K exceeded it, leaving free cash flow of −$1.4M.
Questions
What was Neuroone Medical Technologies' revenue in the second quarter fiscal 2026?
Neuroone Medical Technologies (NMTC) reported revenue of $1.9M for the second quarter fiscal 2026 (Q2 FY26), +34% from a year earlier and -36% from the quarter before.
Was Neuroone Medical Technologies profitable in the second quarter fiscal 2026?
Operating loss was $2.4M (-128.7% of revenue) and net loss $2.4M.